Intranasal sumatriptan: In adolescents with migraine

被引：7

作者：

Curran M.P. ^{[1
,2
]}

Evans H.C. ^{[1
]}

Wagstaff A.J. ^{[1
]}

机构：

[1] Adis International Limited, Auckland

[2] Adis International Limited, Auckland 1311

来源：

CNS Drugs | 2005年 / 19卷 / 4期

关键词：

Migraine; Sumatriptan; Migraine Attack; Butorphanol; Trigeminal Nucleus Caudalis;

D O I：

10.2165/00023210-200519040-00006

中图分类号：

学科分类号：

摘要：

Sumatriptan, a serotonin 5-HT1B/1D agonist, constricts cranial blood vessels and inhibits neuroinflammatory processes. A single dose of sumatriptan 10mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. Headache relief occurred in significantly more adolescents administered a single dose of intranasal sumatriptan 20mg (at 1 and 2 hours) and 5mg (at 2 hours) than placebo (pooled data from two studies). Sustained headache relief (1-24 and 2-24 hours) occurred in significantly more recipients of a single dose of intranasal sumatriptan 20mg and 5mg than placebo (pooled data from two studies). Intranasal sumatriptan was generally well tolerated in adolescent migraineurs (in single-episode studies or long term in multiple-episode studies). Taste disturbance occurred more often with intranasal sumatriptan than with placebo. © 2005 Adis Data Information BV. All rights reserved.

引用

页码：335 / 343

页数：8

共 29 条

[1]

Abu-Arefeh I., Russell G., Prevalence of headache and migraine in schoolchildren, BMJ, 309, pp. 765-769, (1994)

[2]

Hamalainen M., Jones M., Loftus J., Et al., Sumatriptan nasal spray for migraine: A review of studies in patients aged 17 years and younger, Int J Clin Pract, 56, 9, pp. 704-709, (2002)

[3]

Perry C.M., Markham A., Sumatriptan: An updated review of its use in migraine, Drugs, 55, 6, pp. 889-922, (1998)

[4]

Winner P., Rothner A.D., Putnam D.G., Et al., Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database, Headache, 43, 5, pp. 451-457, (2003)

[5]

VanDenBrink A.M., Van Den Broek R.W.M., De Vries R., Et al., Human middle meningeal and coronary artery contraction to eletriptan and Sumatriptan, Cephalalgia, 19, 4, (1999)

[6]

VanDenBrink A.M., Reekers M., Bax W.A., Et al., Coronary side-effect potential of current and prospective antimigraine drugs, Circulation, 98, 1, pp. 25-30, (1998)

[7]

Moore K.H.P., Hussey E.K., Shaw S., Et al., Safety, tolerability, and pharmacokinetics of Sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses, Cephalalgia, 17, 4, pp. 541-550, (1997)

[8]

Nozaki K., Moskowitz M.A., Boccalini P., CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges, Br J Pharmacol, 106, 2, pp. 409-415, (1992)

[9]

Burstein R., Deconstructing migraine headache into peripheral and central sensitisation, Pain, 89, pp. 107-110, (2001)

[10]

Christensen M.L., Mottern R.K., Jabbour J.T., Et al., Pharmacokinetics of sumatriptan nasal spray in adolescents, J Clin Pharmacol, 43, 7, pp. 721-726, (2003)

← 1 2 3 →